Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Timothy Vollmer

Neurology Aurora, CO Medical Doctor

NPI 1669485132 CMS profile 166048

12605 E 16Th Ave, Aurora, CO 80045

Open in the dashboard

General payments

$136,199

109 records reported · program years 2019–2024

Research payments

$49,313

Paid to them · 36 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,860,058 paid to institutions, not to them · program years 2019–2022

Through program year 2024, Timothy Vollmer of Aurora, CO is reported in the CMS Open Payments database as having received $136,199 across 109 general payments and $49,313 in research payments paid to them. Separately, studies naming them as principal investigator received $1,860,058 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2024 Research $10,981 6
2023 General $18,371 8
2023 Research $13,726 13
2022 General $48,015 29
2022 Research $5,820 1
2021 General $12,567 11
2021 Research $6,411 7
2020 General $16,049 10
2020 Research $11,626 7
2019 General $41,197 51
2019 Research $750 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Vollmer
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Timothy Vollmer were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Timothy Vollmer Neurology median Middle half National median
2019 $41,197 $474 $118–$2,177 $163
2020 $16,049 $367 $82–$2,309 $114
2021 $12,567 $438 $104–$2,547 $132
2022 $48,015 $442 $103–$2,388 $149
2023 $18,371 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Genentech USA, Inc. $85,074 54 payments
  2. Genentech, Inc. $16,400 15 payments
  3. EMD Serono, Inc. $16,288 17 payments
  4. F. Hoffmann-La Roche AG $14,183 13 payments
  5. Horizon Therapeutics plc $1,550 1 payment
  6. Novartis Pharmaceuticals Corporation $1,276 1 payment
  7. Celgene Corporation $976 3 payments
  8. Pacira Pharmaceuticals Incorporated $216 2 payments
  9. Actelion Pharmaceuticals, Ltd $125 1 payment
  10. Genzyme Corporation $100 1 payment
  11. Other $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $62,154 27 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $59,602 19 payments
  3. Travel and Lodging $9,388 29 payments
  4. Food and Beverage $3,505 33 payments
  5. Honoraria $1,550 1 payment
Products named General payments · program years 2019–2024
  1. OCREVUS $112,434 78 payments
  2. Non-Covered Product $7,099 8 payments
  3. Mavenclad $6,734 12 payments
  4. Enspryng $1,800 1 payment
  5. UPLIZNA $1,550 1 payment
  6. KESIMPTA $1,276 1 payment
  7. Ozanimod $620 1 payment
  8. Iovera System $216 2 payments
  9. MS DISEASE STATE $100 1 payment
  10. Senza Spinal Cord Stimulation System $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. F. Hoffmann-La Roche AG $35,246 31 payments
  2. Novartis Pharmaceuticals Corporation $14,067 5 payments

Records

145 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record